Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
![](/report_cover/2671/chlamydia-infections-drugs-in-development-by-stages-target-moa-roa-molecule-type-n-key-players-2022-update_en.gif)
Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides an overview of the Chlamydia Infections (Infectious Disease) pipeline landscape.
Chlamydia is a sexually transmitted infection caused by a bacterium. Symptoms include burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods and pain and swelling around the testicles. Predisposing factors include age, multiple sex partners and history of prior sexually transmitted infection. Treatment includes antibiotics and pain medicine.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chlamydia Infections – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chlamydia Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Chlamydia Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chlamydia Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chlamydia Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chlamydia Infections (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chlamydia Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Chlamydia Infections – Overview
Chlamydia Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chlamydia Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chlamydia Infections – Companies Involved in Therapeutics Development
Chlamydia Infections – Drug Profiles
Chlamydia Infections – Dormant Projects
Chlamydia Infections – Product Development Milestones
Featured News & Press Releases
Mar 31, 2022: Evofem presents positive encore data in sexually transmitted infections impacting women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
Mar 04, 2022: Evofem completes enrollment in EVOGUARD Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women
Feb 09, 2022: FDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Jan 04, 2022: Evofem Biosciences to present at H.C. Wainwright BioConnect Conference
Dec 21, 2021: Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
Dec 01, 2021: Eurocine Vaccines Chlamydia vaccine candidate elicits both antibody and T cell responses
Nov 30, 2021: Evofem Biosciences announces successful type C meeting with FDA for STI prevention product candidate
May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021
Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention
Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021
Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Chlamydia Infections – Overview
Chlamydia Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chlamydia Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chlamydia Infections – Companies Involved in Therapeutics Development
Chlamydia Infections – Drug Profiles
Chlamydia Infections – Dormant Projects
Chlamydia Infections – Product Development Milestones
Featured News & Press Releases
Mar 31, 2022: Evofem presents positive encore data in sexually transmitted infections impacting women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
Mar 04, 2022: Evofem completes enrollment in EVOGUARD Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women
Feb 09, 2022: FDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Jan 04, 2022: Evofem Biosciences to present at H.C. Wainwright BioConnect Conference
Dec 21, 2021: Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
Dec 01, 2021: Eurocine Vaccines Chlamydia vaccine candidate elicits both antibody and T cell responses
Nov 30, 2021: Evofem Biosciences announces successful type C meeting with FDA for STI prevention product candidate
May 17, 2021: New data on EVO100 for the prevention of chlamydia and gonorrhea in women to be presented at ISPOR 2021
Mar 31, 2021: Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
Mar 16, 2021: Evofem Biosciences announces publication in American Journal of Obstetrics and Gynecology of AMPREVENCE study of EVO100 for chlamydia and gonorrhea prevention
Feb 25, 2021: Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate
Dec 30, 2020: Eurocine Vaccines advances the development of commercial manufacturing method and updates time plan
Dec 30, 2020: Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
Dec 22, 2020: Evofem Biosciences to participate in Medicaid National Drug Rebate Program for Phexxi effective January 1, 2021
Dec 21, 2020: Evofem Biosciences to present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Chlamydia Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chlamydia Infections – Pipeline by Abera Bioscience AB, 2022
Chlamydia Infections – Pipeline by Abivax SA, 2022
Chlamydia Infections – Pipeline by Aeterna Zentaris Inc, 2022
Chlamydia Infections – Pipeline by BlueWillow Biologics Inc, 2022
Chlamydia Infections – Pipeline by Erganeo, 2022
Chlamydia Infections – Pipeline by Eurocine Vaccines AB, 2022
Chlamydia Infections – Pipeline by Evofem Biosciences Inc, 2022
Chlamydia Infections – Pipeline by Genetic Immunity Inc, 2022
Chlamydia Infections – Pipeline by Lead Discovery Center GmbH, 2022
Chlamydia Infections – Pipeline by Merck & Co Inc, 2022
Chlamydia Infections – Pipeline by Microbiotix Inc, 2022
Chlamydia Infections – Pipeline by QureTech Bio AB, 2022
Chlamydia Infections – Pipeline by Sanofi, 2022
Chlamydia Infections – Pipeline by Traccine Pharmaceuticals, 2022
Chlamydia Infections – Pipeline by Vault Pharma Inc, 2022
Chlamydia Infections – Pipeline by Vaxine Pty Ltd, 2022
Chlamydia Infections – Pipeline by Yaso Therapeutics Inc, 2022
Chlamydia Infections – Dormant Projects, 2022
Number of Products under Development for Chlamydia Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chlamydia Infections – Pipeline by Abera Bioscience AB, 2022
Chlamydia Infections – Pipeline by Abivax SA, 2022
Chlamydia Infections – Pipeline by Aeterna Zentaris Inc, 2022
Chlamydia Infections – Pipeline by BlueWillow Biologics Inc, 2022
Chlamydia Infections – Pipeline by Erganeo, 2022
Chlamydia Infections – Pipeline by Eurocine Vaccines AB, 2022
Chlamydia Infections – Pipeline by Evofem Biosciences Inc, 2022
Chlamydia Infections – Pipeline by Genetic Immunity Inc, 2022
Chlamydia Infections – Pipeline by Lead Discovery Center GmbH, 2022
Chlamydia Infections – Pipeline by Merck & Co Inc, 2022
Chlamydia Infections – Pipeline by Microbiotix Inc, 2022
Chlamydia Infections – Pipeline by QureTech Bio AB, 2022
Chlamydia Infections – Pipeline by Sanofi, 2022
Chlamydia Infections – Pipeline by Traccine Pharmaceuticals, 2022
Chlamydia Infections – Pipeline by Vault Pharma Inc, 2022
Chlamydia Infections – Pipeline by Vaxine Pty Ltd, 2022
Chlamydia Infections – Pipeline by Yaso Therapeutics Inc, 2022
Chlamydia Infections – Dormant Projects, 2022
LIST OF FIGURES
Number of Products under Development for Chlamydia Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development for Chlamydia Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022